William Allan Corp Acquires 2,505 Shares of Zoetis Inc. (NYSE:ZTS)

William Allan Corp boosted its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 16.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,915 shares of the company's stock after buying an additional 2,505 shares during the period. Zoetis accounts for about 1.8% of William Allan Corp's portfolio, making the stock its 24th largest holding. William Allan Corp's holdings in Zoetis were worth $2,950,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Navigoe LLC acquired a new position in Zoetis during the fourth quarter worth $30,000. Cornerstone Planning Group LLC lifted its stake in Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after purchasing an additional 88 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its stake in Zoetis by 87.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after purchasing an additional 120 shares in the last quarter. Murphy & Mullick Capital Management Corp acquired a new position in Zoetis during the fourth quarter worth $44,000. Finally, Sound Income Strategies LLC lifted its stake in Zoetis by 141.4% during the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after purchasing an additional 164 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. UBS Group lowered their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $180.00 to $155.00 in a report on Thursday. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday. Piper Sandler raised their price objective on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Monday, May 12th. Finally, Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and reduced their price objective for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $204.63.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the sale, the executive vice president owned 15,129 shares in the company, valued at $2,571,930. The trade was a 4.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is currently owned by corporate insiders.

Zoetis Stock Down 0.9%

Shares of ZTS traded down $1.29 during mid-day trading on Monday, hitting $147.31. 2,996,578 shares of the company's stock were exchanged, compared to its average volume of 2,624,290. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The firm has a fifty day moving average of $160.77 and a two-hundred day moving average of $161.42. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 1.12. The stock has a market cap of $65.59 billion, a price-to-earnings ratio of 24.68, a P/E/G ratio of 2.46 and a beta of 0.91.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The company had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. During the same period last year, the business posted $1.38 EPS. The business's quarterly revenue was up 1.4% on a year-over-year basis. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.36%. The ex-dividend date is Friday, July 18th. Zoetis's dividend payout ratio is presently 35.91%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.